Microsaic Systems plc
Microsaic (MSYS) , on Friday 16 February, provided an update detailing progress following its recent acquisition of certain assets and intellectual property of the Modern Water business (the ‘Acquisition’), whose integration is going ahead as planned. The same release also detailed new servicing arrangements for the Group’s mass spectrometry (‘MS’) products, including miniaturised PFAS ('forever chemicals') detection equipment that is built around its 4500MiD® units and attracting significant market interest from original equipment manufacturers (‘OEMs’) and suppliers. The Board is now actively resetting both parts of the business, with a view to driving growth and increasing efficiencies, with initial focus on point of need environmental testing of water, including detection of toxic/potentially carcinogenic chemicals.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.